The Replacement Strategy

The Anatomy of a $600 Million Fraud

In April 2019, the U.S. Department of Justice announced that Indivior Inc. and its subsidiary Indivior PLC had been indicted on federal charges of healthcare fraud, mail fraud, and conspiracy to commit wire fraud. The charges centered on Suboxone Film, a dissolvable film containing buprenorphine and naloxone used for opioid addiction treatment.

The indictment alleged that Indivior:

The scheme worked. Between 2010 and 2018, Indivior generated over $3 billion in revenue from Suboxone Film alone. Much of this came directly from state Medicaid programs—meaning American taxpayers were funding the fraud.

The Settlement: $600 Million and No Admission of Guilt

In July 2020, Indivior agreed to pay $600 million to resolve the criminal and civil investigations. The settlement broke down as follows:

• $289 million — Criminal forfeiture and penalties
• $300 million — Civil settlement under the False Claims Act
• Additional state settlements with individual states totaling tens of millions more

Critically, the settlement allowed Indivior to avoid a formal admission of criminal wrongdoing. This is standard practice in pharmaceutical settlements—companies pay massive fines but retain the ability to continue operations without the stigma of a criminal conviction.

The Revenue Model: Creating Lifelong Customers

Understanding Indivior's fraud is crucial, but the more important question is: Why did they do it? The answer lies in the fundamental business model of medication-assisted treatment—a model designed not to cure addiction, but to create permanent pharmaceutical dependency.

The MAT Revenue Stream

Unlike most medications, which are prescribed for a defined treatment period, MAT products like Suboxone are designed for indefinite use. Patients are told they may need to take buprenorphine for months, years, or even life. This creates a recurring revenue stream unlike almost any other pharmaceutical product.

Here's how the economics work:

For a single patient on a 24-month MAT program, the total cost ranges from $14,400 to $36,000. And many patients remain on these programs far longer—some for five years, ten years, or permanently.

This is fundamentally different from treating acute conditions. When you cure a disease, you lose a customer. When you create lifelong dependency, you create perpetual revenue.

The Revolving Door by Design

The MAT industry has carefully constructed a system where "success" is defined not by patients getting off drugs entirely, but by patients remaining on pharmaceutical opioids indefinitely. Treatment centers, doctors, and pharmaceutical companies all have aligned financial incentives to keep patients in the system.

Consider these documented realities:

• Tapering is discouraged. Many MAT programs actively resist patient requests to reduce dosage, citing high relapse rates (which may be caused by improper tapering protocols the industry itself designed).
• Success metrics are distorted. A patient who remains on Suboxone for five years is counted as a "success," even though they've simply traded one dependency for another.
• Alternative approaches are suppressed. Physicians who attempt evidence-based rapid tapering or who recommend kratom as a transition tool risk losing access to the referral network.
• Insurance billing incentivizes continuation. Providers can bill for monthly visits, counseling sessions, and drug tests indefinitely—but only while patients remain in treatment.

This isn't to say buprenorphine doesn't help people. For many facing life-threatening fentanyl addiction, Suboxone can be a necessary stabilization tool. But the difference between medical necessity and financial exploitation lies in what happens next—and the current system is designed to prevent "next" from ever arriving.

The Referral Pipeline: How the System Feeds Itself

The MAT industry doesn't rely solely on pharmaceutical sales. It has constructed an entire ecosystem of mutually reinforcing revenue streams, each designed to capture patients and cycle them through a profitable system indefinitely.

Stage 1: Emergency Departments (The Entry Point)

The pipeline begins in hospital emergency rooms. When someone presents with opioid overdose or withdrawal symptoms, they are increasingly being initiated on buprenorphine directly in the ED—a practice called ED-initiated buprenorphine or "ED bridge" programs.

These programs are often presented as harm reduction—getting people into treatment immediately rather than waiting for outpatient appointments. And in some cases, this can save lives. But the referral patterns reveal a different story.

A 2021 study published in JAMA Network Open found that ED-initiated buprenorphine patients were significantly more likely to enter long-term MAT programs operated by facilities with financial relationships to the initiating hospital. The study did not examine whether these relationships influenced medical decision-making, but the referral patterns suggest a coordinated network rather than neutral clinical judgment.

Stage 2: Detoxification Centers (The Upsell)

For patients deemed to need "higher level of care," the next step is often inpatient detoxification. These facilities—many of which are for-profit operations—bill insurance $500-1,500 per day for what is often little more than supervised withdrawal.

The average detox stay is 5-7 days, generating $2,500-10,500 per patient. Upon discharge, patients are referred to:

• Residential treatment programs ($10,000-30,000 per month)
• Intensive outpatient programs ($5,000-10,000 per month)
• Sober living homes ($500-2,500 per month)
• MAT prescribers (ongoing monthly costs)

Each of these facilities often has referral relationships with one another. A detox center owned by the same parent company as a residential treatment center will naturally refer patients to that facility. A treatment center with a financial interest in sober living homes will recommend their patients transition there.

Stage 3: Residential Treatment (The Long Game)

Residential treatment programs represent the most expensive phase of the pipeline, with costs frequently exceeding $20,000-30,000 per month. These programs typically run 30-90 days, generating $20,000-90,000 per patient.

Upon completion, patients are discharged to:

• Sober living homes — Where they'll pay rent while remaining connected to the treatment network
• Outpatient MAT programs — Where they'll receive ongoing Suboxone prescriptions
• Alumni programs — Which keep patients engaged with the facility for potential future admissions

The treatment center's job is not to cure the patient—it's to transition them into the next revenue-generating phase. Success is measured not by patients leaving the system, but by patients remaining engaged with affiliated services.

Stage 4: Sober Living (The Holding Pattern)

Sober living homes—residential facilities where people in recovery live together—are often the final stage of the pipeline. Residents pay $500-2,500 per month in rent while attending outpatient treatment and seeing MAT prescribers.

These facilities are loosely regulated in most states, creating opportunities for exploitation:

• Homes owned by treatment centers can require residents to attend their programs
• Residents who relapse are sent back to detox or residential treatment (generating new revenue)
• Insurance fraud schemes bill for services never rendered while residents are in sober living
• Some facilities deliberately create conditions that increase relapse risk to generate repeat business

Stage 5: Medication-Assisted Treatment (The Perpetual Revenue Machine)

Throughout every stage of this pipeline, patients remain on Suboxone or similar buprenorphine medications. This is where the pharmaceutical companies make their money—and where the system reveals its true purpose.

Consider a typical patient journey:

• Month 1: Initiated on Suboxone in ED, begins outpatient MAT
• Months 2-3: Enters residential treatment (still on Suboxone)
• Months 4-12: Lives in sober living, continues MAT prescriptions
• Years 2-5: Transitions to independent living but remains on Suboxone "maintenance"
• Years 5+: Told they may need to stay on medication "for life"

At each stage, Indivior and other buprenorphine manufacturers collect revenue. The pharmaceutical companies don't operate the treatment centers or sober living homes—but they benefit from a system that keeps patients on their medications indefinitely.

The Methadone-to-Suboxone Switch: They've Done This Before

This isn't the first time the addiction treatment industry has cycled through a "revolutionary new solution" that turned out to be another profitable trap. To understand where kratom fits into this pattern, we need to examine how Suboxone itself was marketed as the solution to methadone—using the exact same playbook now being deployed against kratom.

The Methadone Era (1960s-2000s)

For decades, methadone was the primary medication-assisted treatment for opioid addiction. Methadone clinics became the standard of care, with patients required to visit daily for observed dosing. The system was heavily regulated, with strict controls on take-home doses.

Methadone worked for many people—but it also created a system of permanent dependency, with patients spending years or decades on the medication. Clinics generated steady revenue through daily dosing fees, and pharmaceutical companies profited from ongoing methadone sales.

But methadone had problems that created an opening for a new product:

• Daily clinic visits were burdensome for patients
• Methadone carried stigma due to clinic settings and patient populations
• Overdose risk was significant, especially during induction phase
• Diversion and misuse were common

These problems were real. But rather than fixing the methadone system, the pharmaceutical industry saw an opportunity to replace it with something more profitable.

Enter Suboxone: The "Safer Alternative"

When buprenorphine products like Suboxone entered the market in the early 2000s, they were marketed as revolutionary improvements over methadone:

These claims drove massive adoption. By 2012, Suboxone had captured significant market share from methadone. Indivior's revenue from Suboxone products exceeded $1.5 billion annually.

But something interesting happened after Suboxone became dominant: the problems that supposedly made it superior to methadone started to emerge in the buprenorphine system as well.

The Pattern Repeats

Within a decade of Suboxone's rise, the same criticisms once leveled at methadone began appearing in medical literature and patient communities:

• Permanent dependency: Patients were staying on Suboxone indefinitely, just as they had with methadone
• Difficult withdrawal: Buprenorphine withdrawal proved to be prolonged and challenging, sometimes worse than methadone
• Diversion and misuse: Black markets for Suboxone emerged, just as they had for methadone
• Financial burden: At $300-600/month, Suboxone was far more expensive than methadone (which costs $10-15/day including clinic fees)
• Lack of support services: Office-based Suboxone prescribing often lacked the counseling and structure that methadone clinics provided

The key insight is this: Suboxone was marketed as the solution to methadone's problems, using the same language now being used to discredit kratom. And once Suboxone became dominant, the industry stopped talking about getting people off medications and started normalizing lifelong pharmaceutical maintenance.

Now, with kratom emerging as a genuinely different alternative—one that can't be patented, costs a fraction of the price, and doesn't require prescribers or insurance billing—the industry is preparing to run the same playbook again.

Insurance Billing: How Taxpayers Fund the System

The MAT industry's profitability doesn't come primarily from patients paying out-of-pocket—it comes from insurance reimbursement, particularly from government programs like Medicaid. Understanding how billing works reveals why the system is designed to keep people in treatment indefinitely.

State Medicaid MAT Spending

Medicaid is the single largest payer for addiction treatment in the United States. According to the Kaiser Family Foundation, Medicaid covered approximately 37% of all non-elderly adults with substance use disorders in 2019. For MAT specifically, Medicaid's share is even higher.

State Medicaid spending on buprenorphine products has increased dramatically:

These figures represent only the cost of the medication itself—not the required doctor visits, counseling sessions, drug testing, or associated treatment services. When those costs are included, total Medicaid MAT spending likely exceeds $5-7 billion annually.

This creates a situation where pharmaceutical companies like Indivior can defraud Medicaid programs (as evidenced by the $600 million settlement) and still profit massively because the underlying billing structure incentivizes ongoing prescriptions regardless of patient outcomes.

State Mandates: Making Buprenorphine Legally Required

Perhaps the most revealing aspect of the MAT industry's influence is the growing number of states that have passed laws essentially mandating buprenorphine access—often in ways that benefit pharmaceutical companies more than patients.

Several states have implemented policies that include:

• Required Medicaid coverage: Mandating that state Medicaid programs cover all FDA-approved MAT medications without prior authorization
• Prescriber incentives: Offering financial bonuses or loan forgiveness to physicians who obtain buprenorphine waivers
• Treatment mandates: Requiring certain populations (such as pregnant women or individuals in criminal justice system) to be offered MAT
• Pharmacy requirements: Prohibiting pharmacies from refusing to stock or dispense buprenorphine products

These policies are often presented as expanding access to care—and in some ways they do. But notice what's absent from these mandates: any requirement that patients ever taper off the medications or any coverage for alternative approaches like kratom.

The Prior Authorization Scam

Part of Indivior's fraud involved manipulating the prior authorization process—the system insurance companies use to control costs by requiring approval before covering expensive medications. Understanding how this worked reveals the depth of the scheme.

Prior authorization is supposed to work like this:

1. Doctor prescribes medication
2. Pharmacy submits claim to insurance
3. Insurance requires justification for expensive brand-name drug when generics exist
4. Doctor provides clinical reasoning
5. Insurance approves or denies based on medical necessity

But Indivior created the "Here to Help" program that bypassed this process:

The brilliance (from a profit perspective) was that Indivior made it easier to prescribe their expensive brand-name product than to prescribe cheaper generics. Doctors naturally gravitated toward the path of least resistance—which happened to be the path Indivior had deliberately engineered.

Why Suboxone Manufacturers Fear Kratom

Now we arrive at the critical question: If the MAT industry has successfully created a multi-billion dollar system of perpetual pharmaceutical dependency, why does kratom pose such a threat?

The answer becomes obvious when you compare the two options side-by-side:

Factor	Suboxone/Buprenorphine	Kratom
Monthly Cost	$300-600 (medication only) $600-1,500 (with required services)	$20-60 (no other requirements)
Prescription Required	Yes — must see licensed physician	No — direct consumer access
Insurance Billing	Yes — generates claims for pharma, doctors, counselors, labs	No — no billable services
Mandatory Counseling	Required by most programs	Optional, user's choice
Mandatory Drug Testing	Required monthly in most programs	None required
Patent Protection	Yes — proprietary formulations	No — natural plant cannot be patented
Manufacturer Control	Complete — pharmaceutical companies control supply	None — anyone can grow or import
Typical Treatment Duration	12-24+ months (often indefinite)	User-determined (many taper off within months)
Withdrawal Difficulty	Prolonged, often requires slow taper over months	Comparable to caffeine for most users
User Autonomy	Low — system controls access, dosing, tapering	High — users control their own use and cessation
Revenue Per Patient (24 months)	$14,400 - $36,000	$480 - $1,440

This comparison table reveals why kratom is an existential threat to the MAT industry. It's not about kratom being dangerous—it's about kratom being economically incompatible with a business model dependent on expensive, controlled, perpetual pharmaceutical treatment.

The Market Math: What's At Stake

Let's calculate exactly how much money the pharmaceutical industry stands to lose if kratom remains legal and accessible—and how much they stand to gain if it's banned.

Current kratom users (conservative estimate): 5 million Americans

Percentage using kratom for opioid withdrawal/maintenance: Approximately 60-70% based on user surveys (3-3.5 million people)

If kratom were banned and these users were forced into pharmaceutical MAT:

This is not a theoretical market—this is the actual number of people currently using kratom who would be forced into pharmaceutical treatment if kratom were scheduled. And unlike other pharmaceutical markets that eventually decline as patents expire or better treatments emerge, the MAT market is designed to grow perpetually as patients remain in the system indefinitely.

For context, Indivior's annual revenue from all Suboxone products peaked at around $2.1 billion. The kratom user base represents a potential market 17 times larger than Indivior's peak Suboxone sales.

The International Dimension

The market opportunity extends far beyond the United States. Pharmaceutical companies are positioning for global MAT expansion, and kratom is legal and widely used in many countries they're targeting.

This explains why Indivior and other manufacturers have supported international scheduling efforts through the World Health Organization. If kratom can be banned globally through WHO recommendations to member states, the entire international market becomes captive to pharmaceutical MAT products.

The pattern is clear: Eliminate the competition first, then capture the market with patented, expensive alternatives.

And we know this pattern works because we've seen it before—with cannabis.

The Pattern: Natural → Banned → Synthetic → Monopoly

When you examine Marinol and Epidiolex together, a clear four-stage pattern emerges:

This playbook has been successfully executed with cannabis/THC/CBD. It's currently being deployed against psilocybin and MDMA (with multiple companies developing patented psychedelic analogs while natural mushrooms remain Schedule I). And it's now being applied to kratom.

Other Examples: The War on Natural Medicine

Cannabis is the most visible example, but the pattern of suppressing natural compounds to enable synthetic monopolies extends across multiple categories:

Psychedelics

As research into psychedelic therapy has advanced, pharmaceutical companies have been filing patents on synthetic analogs and specific treatment protocols:

• COMPASS Pathways: Patented formulation of synthetic psilocybin (identical to natural molecule but synthesized in lab) and specific therapy protocols
• Usona Institute: Attempting to patent psilocybin treatment for depression, despite psilocybin being naturally occurring and in religious use for millennia
• MAPS (MDMA therapy): Developing FDA-approved MDMA-assisted therapy, with treatment costs projected at $15,000+ per course while street MDMA costs $20-40 per dose

Meanwhile, natural psilocybin mushrooms remain Schedule I, and MDMA remains Schedule I despite overwhelming evidence of safety and efficacy in clinical settings.

Opium/Morphine

The original example dates back over a century:

• Natural opium: Used for thousands of years, cheap and accessible
• Morphine (extracted): Patented formulations and delivery systems
• Synthetic opioids: Oxycodone, hydrocodone, fentanyl—all patented, all far more expensive than morphine
• Opium poppies: Illegal to grow in the U.S., while pharmaceutical opioids generated $35 billion in annual sales before the overdose crisis

Coca/Cocaine

Coca leaves have been used safely in Andean cultures for millennia. Cocaine was extracted, weaponized, and commercialized. Now:

• Coca leaves: Illegal in most countries (Schedule II), despite being far less dangerous than extracted cocaine
• Pharmaceutical cocaine: Still used medically, tightly controlled, expensive
• Synthetic alternatives (local anesthetics): Lidocaine, benzocaine, etc.—all patented, all replaced natural coca

Why the Cannabis Precedent Proves Intent

Some might argue that the cannabis/synthetic THC situation was an anomaly—an artifact of the Drug War that persisted due to bureaucratic inertia rather than deliberate strategy. The Epidiolex case proves otherwise.

Epidiolex was approved in 2018—long after the scientific consensus had shifted in favor of cannabis's medical benefits, long after dozens of states had legalized medical cannabis, and long after public opinion had turned decisively against prohibition.

Yet the FDA approved a pharmaceutical CBD product at $32,500 per year while simultaneously maintaining regulatory barriers that prevent natural CBD from being sold with health claims or as a dietary supplement.

This was not an accident. This was a deliberate regulatory strategy designed to:

1. Allow pharmaceutical companies to capture the medical CBD market
2. Prevent natural CBD from competing on equal terms
3. Establish pricing power through patent protection and insurance billing
4. Create precedent for future natural-to-synthetic conversions

The exact same strategy is now being deployed against kratom—with the same players, the same regulatory mechanisms, and the same predicted outcome.

The Kratom Parallel: History Repeating

Let's map the cannabis playbook onto what's happening with kratom right now:

Stage	Cannabis Example	Kratom Status (2024)
Stage 1: Suppress Natural	Schedule I classification (1970) DEA enforcement against growers/sellers	6 states banned kratom DEA scheduling attempts (2016) FDA "public health advisory" campaigns WHO scheduling attempts
Stage 2: Develop Synthetic	Marinol development (1980s) Epidiolex development (2010s)	Multiple patents filed for synthetic mitragynine Clinical trials underway for pharmaceutical versions Companies positioning for FDA approval
Stage 3: Approval + Ban	Marinol approved 1985 (Schedule II) Cannabis remained Schedule I Epidiolex approved 2018 Natural CBD regulatory limbo maintained	NOT YET COMPLETE Awaiting FDA approval of synthetics Then expect DEA emergency scheduling of natural kratom
Stage 4: Market Capture	Marinol: $600-1,800/month Epidiolex: $32,500/year Natural alternatives illegal or restricted	PROJECTED Synthetic kratom: $400-800/month (based on cannabis precedent) Natural kratom: Banned or Schedule I Market value: $36 billion annually

The parallel is not coincidental. It's the same playbook, executed by some of the same companies, using the same regulatory mechanisms, with the same predicted outcome.

The only difference is that with kratom, we can see it happening in real-time—before the synthetic monopoly is established. We have a brief window to prevent what happened with cannabis from happening again.

The Future Under Pharmaceutical Control

Price Projections: The Cannabis Model

Based on the Marinol and Epidiolex precedents, we can estimate pricing for pharmaceutical kratom products:

Compare this to current kratom costs of $20-60 per month, with no other required services. That's a 35-85x price increase for functionally equivalent treatment.

Who Pays?

The pharmaceutical industry will market synthetic kratom products as "FDA-approved medication" eligible for insurance coverage. This means:

• Medicaid will be required to cover it — State mandates will likely require coverage for "FDA-approved addiction treatment"
• Private insurance will cover it — Mental health parity laws require coverage of substance use disorder treatment
• Patients will pay little out-of-pocket — Co-pays of $10-50/month while insurance pays $700-1,700
• Taxpayers and premium-payers absorb the cost — Hidden in Medicaid budgets and insurance premiums

This is the genius of the pharmaceutical pricing model: The people using the medication don't see the true cost, so they have no incentive to seek cheaper alternatives. And if natural kratom is banned, there are no cheaper alternatives to seek.

Access Restrictions: The Gatekeeping System

Beyond price, pharmaceutical control means control over access. Under a prescription model for synthetic kratom, users would face:

Each of these barriers creates friction that prevents or delays access—and each represents an opportunity for the system to extract additional revenue through appointments, testing, counseling, and administrative fees.

The Geographic Divide

Prescription-based access inevitably creates geographic disparities:

• Rural areas: Fewer prescribers, longer travel distances, less access to specialists
• Urban centers: More providers but often concentrated in affluent neighborhoods
• Low-income communities: Fewer private practitioners, reliance on overwhelmed public health systems
• States with restrictive laws: Some states will impose additional barriers beyond federal requirements

Natural kratom, being sold online and in shops, is currently accessible to anyone with internet access or proximity to a vendor. Pharmaceutical kratom would concentrate access among those with insurance, proximity to prescribers, and ability to navigate medical bureaucracy.

Forced Dependency: The MAT Model Applied to Kratom

Perhaps the most insidious aspect of pharmaceutical control is the application of the MAT treatment model—designed to create perpetual pharmaceutical dependency—to a substance that most users currently use temporarily and taper off without medical supervision.

Current Kratom Use Patterns

Surveys of kratom users reveal patterns very different from pharmaceutical MAT:

• Many users take kratom for months to a year while recovering from opioid use, then gradually reduce and stop
• Users self-taper at their own pace without withdrawal symptoms comparable to pharmaceutical opioids
• Some users continue long-term kratom use at low doses similar to coffee consumption
• Users maintain autonomy over dosing, frequency, and cessation

Under pharmaceutical control, this pattern would be replaced with:

This is not hypothetical. This is exactly what happened with Suboxone—which was initially marketed as short-term medication but has evolved into an indefinite maintenance model because that's what generates sustainable revenue.

The Precedent for Everything Else

If pharmaceutical companies successfully ban natural kratom and replace it with synthetic versions, it establishes precedent for doing the same with every other botanical remedy that threatens pharmaceutical profits.

The legal and regulatory mechanisms developed to ban kratom will be refined and reused. The precedent of "natural = dangerous, synthetic = medicine" will be reinforced. And the pathway from botanical use to pharmaceutical dependency will become increasingly unavoidable.

The Total Market Capture

Let's return to the numbers with full context of what pharmaceutical control means:

This is what's at stake. Not public safety. Not addiction prevention. $40-98 billion in annual revenue transfer from individuals to pharmaceutical corporations and the medical-industrial complex.

Why They Can't Afford to Lose

Understanding the scale of this market opportunity explains why the pharmaceutical industry is so aggressive in pursuing kratom scheduling:

• Suboxone market is maturing: Generic buprenorphine has eroded Indivior's pricing power; new revenue sources needed
• Patent cliffs approaching: Many addiction medications losing patent protection; synthetic kratom offers new 20-year monopoly
• Opioid litigation costs: Industry facing tens of billions in settlement costs for opioid crisis; kratom market could offset losses
• Insurance coverage declining: Pushback on MAT program costs; industry needs new covered indication to maintain billing
• International expansion limited: Global MAT growth constrained by kratom availability in key markets

From the pharmaceutical industry's perspective, kratom represents the largest remaining unmonetized addiction treatment market. It's not about whether they should pursue it—from a shareholder value perspective, they have a fiduciary duty to capture this market.

The question is whether we, as a society, are going to allow them to do it.

What You Can Do

The pharmaceutical industry has billions of dollars, armies of lobbyists, and regulatory capture at federal agencies. But they're vulnerable to one thing: public awareness.

When people understand what's actually happening—that this is not about safety but about profits—the political calculus changes. Legislators who take pharmaceutical money and vote for scheduling face electoral consequences. Regulators who serve industry interests over public interest face scrutiny.

The kratom community has already stopped multiple scheduling attempts through grassroots mobilization. The reason this fight continues is because the financial stakes are so enormous that the industry can't afford to give up.

But neither can we.